Displaying drugs 7151 - 7175 of 9780 in total
N-[1H-INDOL-3-YL-ACETYL]GLYCINE ACID
Experimental
3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID
Experimental
3-OXO-N-[(3S)-2-OXOPYRROLIDIN-3-YL]DODECANAMIDE
Experimental
Efaproxiral
Investigational
R-30490
R-30490 is an opioid related to carfentanil used as an animal tranquilizer. It was first synthesized by Janssen Pharmaceutica as part of a structure-activity relationship study of fentanly and its derivatives. R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl...
Experimental
2-chloroethyl-3-sarcosinamide-1-nitrosourea
2-chloroethyl-3-sarcosinamide-1-nitrosourea has been used in trials studying the treatment of Colorectal Cancer, Brain and Central Nervous System Tumors, and Unspecified Adult Solid Tumor, Protocol Specific.
Investigational
Olumacostat glasaretil
Olumacostat glasaretil has been used in trials studying the treatment of Acne Vulgaris.
Investigational
Felcisetrag
Felcisetrag (TD-8954) has been used in trials studying the treatment of Enteral Feeding Intolerance and Gastrointestinal Motility Disorder.
Investigational
2-(2-HYDROXY-CYCLOPENTYL)-PENT-4-ENAL
Experimental
JTK-853
JTK-853 has been used in trials studying the treatment of Hepatitis C Virus Infection, Response to Therapy of.
Investigational
NX-210c
Investigational
Arginineamide
Experimental
Phenacetin
Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn
N-Acetylalanine
Experimental
Taselisib
Taselisib has been used in trials studying the treatment and basic science of LYMPHOMA, Breast Cancer, Ovarian Cancer, Solid Neoplasm, and HER2/Neu Negative, among others.
Investigational
Emapunil
Emapunil has been used in trials studying the basic science and diagnostic of Baseline, Blocking Receptor Binding, and Neurodegenerative Disorders.
Investigational
Alpha-N-Dichloroacetyl-P-Aminophenylserinol
Experimental
Displaying drugs 7151 - 7175 of 9780 in total